Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Short Communication Volume 3 Issue 10

A Review on Teicoplanin Used as Alternative Drug to Treat the Novel Corona Virus (COVID – 19)

Anirban Adhikary1*, Kakoli Halder1, Debmalya Ghosh1, Snehansu Biswas2, Indranil Chatterjee2 and Suman Kumar Nath2

1B Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India
2Assistant Professor, Birbhum Pharmacy School, Birbhum, West Bengal, India

*Corresponding Author: Anirban Adhikary, B. Pharm, Birbhum Pharmacy School, Birbhum, West Bengal, India.

Received: August 24, 2020; Published: September 16, 2020

×

Abstract

  In December 2019, another coronavirus, named SARS-CoV-2, has risen up out of China causing pneumonia episodes first in the Wuhan locale and have now spread overall in view of its plausible high transmission productivity. Because of the absence of productive and explicit medicines and the need to contain the pestilence, medicate repurposing has all the earmarks of being the best instrument to discover remedial arrangement. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have demonstrated viability to restrain coronavirus in vitro. Teicoplanin, an anti-microbial used to treat staphylococci disease, recently demonstrated adequacy to hinder the principal phase of MERS coronavirus viral cycle in human cells. This action is preserved on the SARS-Cov-2, accordingly putting teicoplanin as an expected treatment for patients with this infection.

Keywords: SARS-CoV-2; Drug Repurposing; Teicoplanin; COVID-19

×

References

  1. Zhu N., et al. “A Novel Coronavirus from Patients with Pneumonia in China, 2019”. The New England Journal of Medicine 382 (2020): 727-733.
  2. Lai C-C., et al. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges”. International Journal of Antimicrobial Agents (2020): 105924.
  3. Devaux C., et al. “New insights for antiviral effects of chloroquine against coronavirus: what to expect for COVID 19?” International Journal of Antimicrobial Agents (2020).
  4. Wang M., et al. “Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro”. Cell Research (2020).
  5. Colson P., et al. “Chloroquine for the 2019 novel coronavirus SARSCoV-2”. International Journal of Antimicrobial Agents (2020): 105923.
  6. Ko W-C., et al. “Remdesivir for SARS-CoV-2 pneumonia”. International Journal of Antimicrobial Agents (2020).
  7. Zhang J., et al. “Teicoplanin potently blocks the cell entry of 2019-nCoV”. BioRxiv (2020).
  8. Zhou N., et al. “Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)”. Journal of Biological Chemistry 291 (2016): 9218-9232.
  9. Colson P and Raoult D. “Fighting viruses with antibiotics: an overlooked path”. International Journal of Antimicrobial Agents 48 (2016): 349-352.
  10. Pan T., et al. “Use of teicoplanin anti-middle east respiratory syndrome coronavirus”. WO/2016/201692 (2015).
×

Citation

Citation: Anirban Adhikary., et al. “A Review on Teicoplanin Used as Alternative Drug to Treat the Novel Corona Virus (COVID – 19)". Acta Scientific Microbiology 3.10 (2020): 59-60.



Indexed In






News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 20, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US